Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

NCT ID: NCT00573755

Last Updated: 2016-02-05

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-12-31
• Study Completion Date: 2013-04-30

Brief Summary

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Aromatase inhibition therapy using letrozole, anastrozole, or exemestane may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether sorafenib is more effective than a placebo when given together with letrozole, anastrozole, or exemestane in treating metastatic breast cancer.

PURPOSE: This randomized phase II trial is studying how well sorafenib works compared with a placebo when given together with letrozole, anastrozole, or exemestane in treating postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive metastatic breast cancer.

Detailed Description

OBJECTIVES:

Primary

• To compare the progression-free survival of postmenopausal women with estrogen receptor- and/or progesterone receptor-positive metastatic breast cancer treated with sorafenib tosylate vs placebo and letrozole, anastrozole, or exemestane.

Secondary

• To compare the overall survival and time to treatment failure of patients treated with these regimens.
• To compare the objective tumor response rate and duration of response in patients treated with these regimens.
• To assess the adverse event profile of sorafenib tosylate in combination with aromatase inhibitors in these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to prior aromatase inhibitor therapy (yes vs no) and line of endocrine therapy for metastatic disease (first-line vs second-line). Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28.
• Arm II: Patients receive oral placebo twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28.

In both arms, treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically for up to 5 years.

Conditions

Breast Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Arm I

Patients receive oral sorafenib tosylate twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

anastrozole

Intervention Type: DRUG

given orally

exemestane

Intervention Type: DRUG

given orally

letrozole

Intervention Type: DRUG

given orally

sorafenib tosylate

Intervention Type: DRUG

given orally

Arm II

Patients receive oral placebo twice daily and oral letrozole, anastrozole, or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Group Type: ACTIVE_COMPARATOR

anastrozole

Intervention Type: DRUG

given orally

exemestane

Intervention Type: DRUG

given orally

letrozole

Intervention Type: DRUG

given orally

placebo

Intervention Type: OTHER

given orally

Interventions

anastrozole

given orally

Intervention Type: DRUG

exemestane

given orally

Intervention Type: DRUG

letrozole

given orally

Intervention Type: DRUG

sorafenib tosylate

given orally

Intervention Type: DRUG

placebo

given orally

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed adenocarcinoma of the breast

• Metastatic disease
• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (i.e., MRI or CT scan of chest, abdomen and pelvis) or ≥ 10 mm by spiral CT scan

• Non-measurable disease allowed, defined as all other lesions (or sites of disease), including small lesions (longest diameter < 20 mm by conventional techniques or < 10 mm by spiral CT scan)
• Must have objective evidence of progression within the past 3 months
• No human epidermal growth factor receptor 2 (HER2)/neu overexpression, defined as gene amplification by fluorescence in situ hybridization or 3+ overexpression by immunohistochemistry, or unknown HER2/neu status
• No active brain metastases

• Patients with neurological symptoms must undergo a contrast CT scan or MRI of the brain to exclude active brain metastasis
• Patients with treated brain metastases allowed provided they have no evidence of disease and have been off definitive therapy (including steroids) for the past 3 months
• Hormone receptor status:

• Estrogen receptor- and/or progesterone receptor-positive disease

PATIENT CHARACTERISTICS:

• Female
• The Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• Postmenopausal
• Hemoglobin ≥ 9.0 g/dL
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement)
• INR ≤ 1.5
• PTT within normal limits
• Creatinine ≤ 1.5 times ULN
• Not nursing, pregnant, or able to become pregnant
• No significant traumatic injury within the past 4 weeks
• No history of bleeding diathesis or uncontrolled coagulopathy
• No serious, nonhealing wound, ulcer, or bone fracture
• No clinically significant cardiac disease, including any of the following:

• New York Heart Association class III-IV congestive heart failure
• Unstable angina (i.e., anginal symptoms at rest) or new-onset angina (i.e., began within the past 3 months)
• Myocardial infarction within the past 6 months
• No cardiac ventricular arrhythmias requiring antiarrhythmic therapy
• No uncontrolled hypertension (systolic BP > 150 mm Hg or diastolic BP > 90 mm Hg), despite optimal medical management
• No thrombolic, embolic, venous, or arterial events (e.g., cerebrovascular accident including transient ischemic attacks) within the past 6 months
• No pulmonary hemorrhage or bleeding event > grade 2 within the past 4 weeks
• No other hemorrhage or bleeding event ≥ grade 3 within the past 4 weeks
• No active clinically serious infection > grade 2
• No known HIV infection
• No chronic hepatitis B or C infection
• No previous or concurrent cancer that is distinct in primary site or histology from breast cancer except carcinoma in situ of the cervix, treated basal cell skin cancer, superficial bladder tumors (i.e., Ta and Tis), or any cancer curatively treated within the past 5 years
• No known or suspected allergy to sorafenib tosylate or other agents used in this study

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No major surgery or open biopsy within the past 4 weeks
• No more than 1 prior regimen of endocrine therapy for metastatic breast cancer, provided that the patient has not received an aromatase inhibitor within the past 12 months
• No more than 1 prior regimen of chemotherapy for metastatic disease
• More than 2 weeks since prior radiotherapy, except if to a non-target lesion only or single-dose radiotherapy for palliation

• Prior radiotherapy to a target lesion(s) is permitted only if there has been clear progression of the lesion since radiotherapy was completed
• Concurrent anticoagulation treatment (e.g., warfarin or heparin) allowed
• No concurrent Hypericum perforatum (St. John's wort), rifampin, bevacizumab, or any other drugs (licensed or investigational) that target vascular endothelial growth factor (VEGF) or VEGF receptors
• No concurrent cytochrome P450 enzyme-inducing anti-epileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 120 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Mayo Clinic

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Vivek Roy, MD

Role: STUDY_CHAIR

Mayo Clinic

Donald W Northfelt, M.D.

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Timothy J Hobday, M.D.

Role: PRINCIPAL_INVESTIGATOR

Mayo Clinic

Locations

Mayo Clinic in Arizona

Scottsdale, Arizona, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

P30CA015083

Identifier Type: NIH

Identifier Source: secondary_id

View Link

RC0731

Identifier Type: OTHER

Identifier Source: secondary_id

07-005768

Identifier Type: OTHER

Identifier Source: secondary_id

RC0731

Identifier Type: -

Identifier Source: org_study_id